Pending Food and Drug Administration approval of bemotrizinol: A potential turning point for United States sunscreen formulation

Authors

• Steven Q Wang
• Uli Osterwalder
• Henry W. Lim, Henry Ford HealthFollow

Recommended Citation

Wang SQ, Osterwalder U, Lim HW. Pending FDA Approval of Bemotrizinol: A Potential Turning Point for U.S. Sunscreen Formulation. J Am Acad Dermatol. 2026;95(3):891-893.

Document Type

Article

Publication Date

9-1-2026

Publication Title

Journal of the American Academy of Dermatology

PubMed ID

42067042

ePublication

ePub ahead of print

Volume

95

Issue

3

First Page

891

Last Page

893